Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib

Journal of Clinical Oncology

Volumn 25, Issue 23, 2007, Pages 3544-3546

  Saylor, Philip J ^a   Reid, Tony R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; SUNITINIB;

ACUTE KIDNEY FAILURE; ADULT; ANAMNESIS; ARTICLE; CANCER GROWTH; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DRUG DOSE REDUCTION; GASTROINTESTINAL STROMAL TUMOR; HOSPITAL ADMISSION; HUMAN; LABORATORY TEST; LIVER METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SEROSA; TUMOR LYSIS SYNDROME; TUMOR VOLUME;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; FATAL OUTCOME; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRROLES; TUMOR LYSIS SYNDROME;

EID: 34548176054     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.0790     Document Type: Article

References (7)

1. Tsokos GC, Balow JE, Spiegel RJ, et al: Renal and metabolic complications of undifferentiated and lymphoblastic lymphomas. Medicine 60:218-229, 1981
2. Hasegawa T, Matsuno Y, Shimoda T, et al: Gastrointestinal stromal tumor: Consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol 33:669-676, 2002
3. Edmonson JH, Marks RS, Buckner JC, et al: Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Invest 20:605-612, 2002
4. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002
5. Demetri GD, van Oosterom AT, Garrett CR, et al: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomized controlled trial. Lancet 368:1329-1338, 2006
6. Faivre S, Delbaldo C, Vera K, et al: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35, 2006
7. Chow LQM, Eckhardt SG: Sunitinib: From rational design to clinical efficacy. J Clin Oncol 25:884-896, 2007